Provention bio announces $125 million term loan facility with hercules capital

Red bank, n.j. , aug. 31, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the company has secured a term loan facility of up to $125 million with hercules capital, inc. (nyse: htgc), a leader in customized financing for companies in life sciences.
PRVB Ratings Summary
PRVB Quant Ranking